CORT at a glance
Corcept Therapeutics Inc (CORT, SEC CIK 1088856) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Corcept Therapeutics Inc (CORT) reported revenue of $761.4 million (up 12.8% from FY2024) and net income of $99.7 million. Diluted EPS was $0.82.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Corcept Therapeutics Inc (CORT) shares worth $3.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Vieira Roberto Wandenkolk on October 2, 2026 of 2,086 shares at $115.73 per share.
- In the last 90 days, CORT insiders reported 0 open-market purchases ($0) and 64 open-market sales ($57.2M) on Form 4, a net sale of $57.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $761.4M
- +12.8% vs prior year
- Insiders · 90 days
- 0 buys · 64 sells
- Net −$57.2M
- 13F holders
- 35 funds
- $3.9B · +1 vs prior quarter
- Latest 10-Q
- Jul 29, 2026
- Quarterly report
SignalX for CORT
Don't miss the next CORT filing
- Alerts as it files. A push when CORT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CORT, by share count.
- Ask anything. An AI agent that reads every CORT filing and answers with sources.
CORT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Vieira Roberto Wandenkolk | Sell | Oct 2, 2026 | 2,086 | $115.73 |
| Vieira Roberto Wandenkolk | M | Oct 2, 2026 | 8,333 | - |
| Vieira Roberto Wandenkolk | Sell | Oct 2, 2026 | 1,100 | $114.52 |
| Vieira Roberto Wandenkolk | M | Oct 2, 2026 | 8,333 | $21.63 |
| Maduck Sean | M | Oct 2, 2026 | 24,587 | $8.27 |
| Vieira Roberto Wandenkolk | Sell | Oct 2, 2026 | 5,147 | $116.58 |
| Maduck Sean | Sell | Oct 2, 2026 | 8,744 | $116.55 |
| Maduck Sean | Sell | Oct 2, 2026 | 15,843 | $116.12 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $675.0M | $761.4M |
| Operating Income | - | $137.0M | $44.8M |
| Net Income | $106.1M | $141.2M | $99.7M |
| Op. Margin | - | 20.3% | 5.9% |
| Net Margin | - | 20.9% | 13.1% |
| Balance Sheet | |||
| Total Assets | $621.5M | $840.6M | $836.7M |
| Equity | - | $679.6M | $647.8M |
| ROE | - | 20.8% | 15.4% |
| Per Share | |||
| EPS | $0.94 | $1.23 | $0.82 |
| Cash Flow | |||
| Operating CF | - | $198.1M | $142.0M |
| CapEx | $139K | $2.2M | $211K |
Source: XBRL data in Corcept Therapeutics Inc (CORT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CORT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $3.90B |
| Q1 2026 | 34 | $1.76B |
| Q4 2025 | 33 | $1.51B |
| Q3 2025 | 34 | $3.75B |
| Q2 2025 | 33 | $3.20B |
| Q1 2025 | 30 | $3.64B |
| Q4 2024 | 24 | $1.49B |
| Q3 2024 | 21 | $855.6M |
- AQR Capital Management+2.18M (+536%)
- BlackRock+280.7K (+2%)
- Vanguard Portfolio Management LLC+224.1K (+5%)
- Bank of America Corp+216.8K (+194%)
- FMR LLC (Fidelity)+147.4K (+5%)
- Renaissance Technologies LLC−421.2K (-7%)
- Millennium Management−406.2K (-73%)
- Two Sigma Investments−335.8K (-36%)
- D.E. Shaw & Co−298.3K (-25%)
- Citigroup−279.3K (-66%)
- Citizens Financial Group+4.0K
- Allstate+2.9K
- HANCOCK WHITNEY CORP−10.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 244 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CORT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CORT SEC filings: frequently asked questions
Are CORT insiders buying or selling?
In the last 90 days, Corcept Therapeutics Inc (CORT) officers, directors and 10% owners reported no open-market purchases and 64 open-market sales worth $57.2 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CORT stock?
As of June 30, 2026, the largest Corcept Therapeutics Inc (CORT) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Renaissance Technologies LLC ($457.5 million), Vanguard Portfolio Management LLC ($438.6 million), Vanguard Capital Management LLC ($362.8 million), FMR LLC (Fidelity) ($290.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CORT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Corcept Therapeutics Inc (CORT) reported revenue of $761.4 million (up 12.8% from FY2024) and net income of $99.7 million. Diluted EPS was $0.82. The figures come from the XBRL data in the 10-K.
What are the latest CORT SEC filings?
Corcept Therapeutics Inc (CORT) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on October 5, 2026.
What is CORT's SEC CIK number?
Corcept Therapeutics Inc (CORT)'s SEC Central Index Key (CIK) is 1088856. EDGAR lists every CORT filing under that number.
Ask anything about CORT
The research agent reads CORT's filings, financials, insider trades and 13F holders, then answers with sources.